Editorial
ALK-Abelló is well prepared for the challenges that lie ahead. In recent years, ALK-Abelló has increased growth in its core business, launched new products, and has innovative new products in the pipeline.
Highlights 2004/05
ALK-Abelló’s revenue totalled DKK 1,217 million (1,054) equivalent to organic growth of 15%, up from the latest forecast of 12%. For the 2005/06 financial year organic growth is expected in the range of 8-10%.
About the annual report
With the divestment of Chr. Hansen this is the last annual report of Chr. Hansen Holding A/S. The new listed company, ALK-Abelló A/S, will continue the high level of disclosure.
Value drivers
ALK-Abelló is a specialist in a niche market. The company produces and markets allergy vaccines for patients with specific diagnoses.